Bryce Point Capital LLC Purchases New Stake in Natera, Inc. (NASDAQ:NTRA)

Bryce Point Capital LLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 11,939 shares of the medical research company’s stock, valued at approximately $1,890,000. Natera accounts for about 0.5% of Bryce Point Capital LLC’s holdings, making the stock its 18th biggest position.

Other large investors also recently made changes to their positions in the company. The Manufacturers Life Insurance Company increased its holdings in Natera by 87.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company’s stock valued at $8,621,000 after purchasing an additional 31,649 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Natera by 5.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,339 shares of the medical research company’s stock valued at $3,344,000 after buying an additional 1,263 shares in the last quarter. Captrust Financial Advisors grew its stake in shares of Natera by 108.7% in the third quarter. Captrust Financial Advisors now owns 5,689 shares of the medical research company’s stock valued at $722,000 after buying an additional 2,963 shares in the last quarter. Paloma Partners Management Co purchased a new stake in shares of Natera during the 3rd quarter valued at about $238,000. Finally, Benjamin Edwards Inc. lifted its position in Natera by 15,167.3% during the 3rd quarter. Benjamin Edwards Inc. now owns 7,481 shares of the medical research company’s stock worth $950,000 after acquiring an additional 7,432 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling at Natera

In other news, CEO Steven Leonard Chapman sold 9,563 shares of Natera stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $1,323,614.83. Following the sale, the chief executive officer now owns 212,541 shares of the company’s stock, valued at approximately $29,417,799.81. The trade was a 4.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 2,562 shares of the business’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total value of $354,606.42. Following the transaction, the chief financial officer now owns 75,557 shares of the company’s stock, valued at approximately $10,457,844.37. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 318,922 shares of company stock worth $50,619,104. 7.60% of the stock is owned by insiders.

Natera Price Performance

NTRA opened at $140.65 on Wednesday. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average price is $158.72 and its 200 day moving average price is $151.35. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The firm has a market cap of $19.01 billion, a price-to-earnings ratio of -79.91 and a beta of 1.80.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analysts’ expectations of $447.91 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. As a group, sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

NTRA has been the topic of a number of analyst reports. Royal Bank of Canada initiated coverage on shares of Natera in a research note on Thursday, March 13th. They set an “outperform” rating and a $251.00 price objective on the stock. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research note on Wednesday, March 19th. Barclays started coverage on shares of Natera in a research report on Thursday, January 23rd. They issued an “overweight” rating and a $200.00 price objective for the company. Guggenheim lifted their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Finally, Robert W. Baird increased their price target on Natera from $183.00 to $188.00 and gave the company an “outperform” rating in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Natera presently has a consensus rating of “Moderate Buy” and a consensus target price of $178.12.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.